-
04.06.2021 | CARB-X is funding Novel Microdevices to develop a rapid and portable diagnostic for sexually transmitted diseases including antibiotic-resistant infections
CARB-X is awarding Novel Microdevices, Inc. of Baltimore, Maryland, USA, up to $3.6 million in non-dilutive funding, and, subject to available funding, up to an additional $10.2 million if certain project milestones are met, to develop a new rapid molecular test to diagnose sexually-transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae.
-
03.30.2021 | CARB-X is funding University of Oxford’s Jenner Institute to develop a new vaccine to prevent gonorrhea
CARB-X is awarding up to US$2 million to the Jenner Institute, part of the University of Oxford, UK, to develop a novel vaccine to prevent gonorrhea, a common sexually-transmitted bacterial infection that has developed resistance to most antibiotics. Under the award, the Institute would be eligible for up to $5.3 million more if the project progresses through certain project milestones, subject to available funding.
-
03.22.2021 | World’s leading funders of antibacterial research provide guidance on Stewardship and Access in the fight against antibiotic-resistant bacteria
Leading funders of research and development of new antibiotics and other products targeting antibiotic-resistant bacteria have just released a document providing comprehensive guidance on strategies and activities to support Stewardship and Access for companies bringing new antibacterial products to market. The Stewardship and Access Plan Development Guide provides companies with a framework to develop plans so that their product will be used responsibly, minimizing the spread of antibiotic-resistant bacteria while helping patients get access to life-saving products.
-
03.09.2021 | CARB-X is funding Affinivax to develop a novel vaccine to prevent Staphylococcus aureus bacterial infections
CARB-X is funding Affinivax, a Cambridge, Massachusetts, USA, biotech, to develop a new vaccine that will prevent Staphylococcus aureus bacterial infections, healthcare-associated infections that are a major health threat particularly to high-risk and older patients.
-
03.01.2021 | CARB-X is funding GSK to support the development of two unique vaccine projects that aim to prevent serious bacterial infections killing thousands worldwide each year
CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH), based in Siena, Italy, to develop new vaccines to prevent serious infections caused by two different pathogens. Together, the two awards could be worth potentially more than $18 million if project milestones are met, subject to available funding.
-
02.22.2021 | CARB-X is funding The University of Queensland to develop a new drug targeted to low- and middle-income countries that would breathe new life into existing readily-available antibiotics in the fight against drug-resistance
CARB-X is awarding up to US$2.2 million to The University of Queensland’s (UQ) Institute for Molecular Bioscience (IMB) to expand its Octapeptin research program to develop a new drug designed for use in low- and middle-income countries (LMICs) where there are high levels of drug-resistant bacteria.
-
02.03.2021 | CARB-X is funding French biotech Mutabilis to develop a new class of antibacterials to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria
CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria.
-
02.01.2021 | CARB-X is funding the development of Avails Medical’s rapid antibiotic susceptibility testing technology to identify the most effective antibiotic therapy for serious blood infections
CARB-X is funding Avails Medical, a Menlo Park, CA, USA, diagnostics company, to develop an electronic antibiotic susceptibility testing (AST) device to speed up health care providers’ ability to determine the most effective antibiotic treatment for serious and life-threatening blood infections.
-
01.27.2021 | CARB-X is funding Seattle-based Lumen Bioscience to develop a new oral monoclonal antibody cocktail to prevent serious diarrheal diseases
CARB-X is awarding up to US$5.35 million to Lumen Bioscience, in Seattle, WA, USA, to develop a new immunotherapy to prevent diarrheal diseases caused by two deadly pathogens, Campylobacter jejuni and enterotoxigenic E. coli.
Toggle navigation